2/25/2021 4:17:00 PM
Nektar Therapeutics Q4 Loss/share $0.65 Vs. Loss $0.64 Year Ago
2/17/2021 8:11:58 AM
Nektar Announces Agreement For Phase 2/3 Study Of Bempegaldesleukin In Combination With KEYTRUDA
2/17/2021 8:10:39 AM
Nektar Announces Collaboration With SFJ Pharma To Support Development Of Bempegaldesleukin In Head And Neck Cancer
1/5/2021 4:21:35 PM
Nektar Appoints Brian Kotzin As Interim Chief Medical Officer And Head Of Development
12/22/2020 8:31:46 AM
Nektar Therapeutics Enters Agreement With Healthcare Royalty To Sell ADYNOVATE And MOVANTIK Royalties For $150 Mln
12/15/2020 8:31:58 AM
Nektar Therapeutics Says First Patient Dosed In Phase 1/2 Trial Of NKTR-255
11/12/2020 8:01:28 AM
William Blair Reiterates Nektar Therapeutics (NKTR) At Outperform
11/5/2020 4:18:04 PM
Nektar Therapeutics Q3 Loss/Shr $0.61 Vs $0.56 Last Year
10/27/2020 7:33:58 AM
Nektar Therapeutics Received FDA Clearance For IND Application For Investigational IL-2 Pathway Agent, Bempegaldesleukin
8/12/2020 8:07:29 AM
Vaccibody And Nektar Therapeutics Announce First Patient Dosed In Phase 1/2a Study Arm Evaluating VB10.NEO With NKTR-214
8/6/2020 4:19:35 PM
Nektar Q2 Loss/Shr $0.45 Vs Loss $0.63 Last Year